NasdaqGM:FOLDBiotechs
Amicus Therapeutics (FOLD): Assessing Valuation After a 30% Monthly and 65% Three-Month Share Price Surge
Amicus Therapeutics (FOLD) has quietly delivered a strong run lately, with the stock climbing over 30% in the past month and roughly 65% over the past 3 months.
See our latest analysis for Amicus Therapeutics.
That surge sits on top of a solid backdrop, with the share price return over the past year also firmly positive. This suggests sentiment is shifting toward Amicus as its rare disease portfolio matures and execution risks feel lower.
If Amicus has sparked your interest, it is worth...